Aller au contenu principal
2026 conference-abstract

Abstract LB099: Whole-genome analysis identifies novel molecular subtypes and driver structural variants in Japanese ovarian cancer

0Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract Ovarian cancer is a heterogeneous disease comprising a number of histotypes that are associated with distinct clinical characteristics such as therapeutic efficacy and likelihood of relapse. Since ovarian cancer exhibits heterogeneity even within a same histotype, it is critical to develop a complementary classification framework. Whereas for endometrial cancer, a molecular subtyping scheme based on genomic features was developed by The Cancer Genome Atlas (TCGA) and the scheme has been currently integrated into the system of 2020 WHO classification of Female Genital Tract tumour, large-scale genomic studies of ovarian cancer have predominantly focused on high-grade serous (HGS), a major histotype in Caucasian populations. The remaining histotypes exemplified by clear cell carcinoma, which is uniquely prevalent in the East Asian population, have not been covered by these studies, and therefore genomic features that can be utilized for molecular subtyping have not been well characterized for non-HGS ovarian cancer. To address this gap, we performed whole-genome sequencing of 1,412 Japanese ovarian cancers across six major histotypes: clear cell, high-grade serous, endometrioid, mucinous, carcinosarcoma, and sex cord-stromal tumors. Integrative whole-genome analysis identified five molecular subtypes—POLE, MSI, CNH-A, CNH-B, and CNL—with distinct genomic and clinicopathological features. CNH-A represented a conventional copy-number-high subtype characterized by frequent BRCA1 deletions and genomic features of homologous recombination deficiency, whereas CNH-B tumors showed frequent ATM alterations and copy-number variations (CNVs) with retained heterozygosity. Pathogenic germline variants in hereditary cancer genes exhibited histotype-specific patterns, and tumors with biallelic alterations in homologous recombination genes showed high HRD scores, accompanied by distinct somatic CNVs and structural variations (SVs). Furthermore, across 1,349 evaluable cases, we identified 101 genomic regions harboring candidate driver SVs, including 11 known driver regions and 20 fragile sites, as well as 70 previously unreported candidate driver SV regions. Together, this whole-genome analysis defines molecular subtypes characterized by distinct copy-number architectures and identifies recurrent driver SVs, providing a basis for refined molecular classification and future precision oncology. Citation Format: Osamu Gotoh, Takaki Ishizuka, Norio Tanaka, Tetsuo Noda, Seiichi Mori. Whole-genome analysis identifies novel molecular subtypes and driver structural variants in Japanese ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB099.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Abstract LB099: Whole-genome analysis identifies novel molecular subtypes and driver structural variants in Japanese ovarian cancer
Date Crossref
17/04/2026
Éditeur
American Association for Cancer Research (AACR)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cancer Genomics and DiagnosticsOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.